Form 4: INSMED CFO Executes Pre-Planned Stock Option Exercises and Share Sales

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, executed pre-planned transactions on July 7, 2025, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 trading plan.

Summary

• Sara Bonstein, Chief Financial Officer of INSMED Inc., engaged in multiple stock transactions on July 7, 2025, as reported in a Form 4 filing.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
• Bonstein acquired a total of 47,888 shares of common stock through the exercise of stock options at prices ranging from $19.74 to $26.46 per share.
• Concurrently, she disposed of a total of 57,764 shares of common stock through sales.
• The sales occurred at weighted average prices of $95.66 per share for 35,583 shares (ranging from $95.01 to $96.00) and $96.19 per share for 22,181 shares (ranging from $96.01 to $96.95).
• Following these reported transactions, Sara Bonstein's direct beneficial ownership of INSMED common stock stands at 84,017 shares.
• The reported beneficial ownership also includes 357 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
• Remaining derivative securities include stock options with exercise prices ranging from $19.74 to $26.46, with various vesting schedules and expiration dates up to January 5, 2033.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there is a net sale of shares by a key executive, the transactions were pre-planned under a 10b5-1 plan, which reduces the negative signal often associated with insider selling. Furthermore, the significant profit realized by the CFO from exercising options at much lower prices than the sale prices indicates a positive outcome for the insider and reflects the company's stock appreciation.

Positives

• The Chief Financial Officer exercised stock options at significantly lower prices ($19.74 to $26.46) compared to the sale prices ($95.66 to $96.19), indicating substantial personal profitability from long-held equity incentives.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a structured approach to insider trading and mitigates concerns about opportunistic selling based on non-public information.

Negatives

• The Chief Financial Officer sold a significant number of shares (57,764 shares), resulting in a net reduction of 9,876 shares in direct beneficial ownership from these specific transactions, which could be perceived as a reduction in insider conviction, despite being pre-planned.

Future Outlook

This Form 4 filing primarily reports past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

This Form 4 filing details specific insider trading activity for INSMED Inc. and does not provide broader industry context or trends. Insider transactions are common across all industries as executives manage their equity compensation.

Corporate Governance

Related Party Transactions

• The reported transactions involve the Chief Financial Officer of INSMED Inc. exercising stock options and selling company common stock, which are considered related party transactions due to the insider's relationship with the issuer.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even if pre-planned, could be viewed with slight caution, but the execution under a 10b5-1 plan generally mitigates concerns about opportunistic selling. The profitability of the option exercises reflects positively on the company's stock performance.
• Employees: The exercise of stock options and participation in an Employee Stock Purchase Plan (ESPP) highlight the company's equity compensation programs, which can be a positive for employee retention and motivation.

Next Steps

• The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the reported price ranges upon request.

Key Dates

Keywords

INSMED Inc., INSM, Form 4, Insider Trading, Stock Options, CFO, Share Sale, 10b5-1 Plan, Beneficial Ownership, Equity Compensation